(thirdQuint)Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women.

 Hypothesis: Mirabegron is effective in reducing symptoms in women with pain related urinary frequency and urgency.

 Specific Aims: 1.

 To measure the efficacy of Mirabegron in the treatment of frequency and urgency, using voiding diaries.

 2.

 To measure the number of patients with a 50% or greater reduction in frequency and urgency, using voiding diaries.

 3.

 To measure the number of patients with a 50% or greater reduction in bladder pain as measured in the O'Leary-Sant (OLS) IC symptom and problem, and the Lowell Parsons Pelvic Pain and Urgency/Frequency (PUF) patient symptom scale.

 Intervention/Project goal: Treatment with Mirabegron 25mg for 4 weeks with an option for dose escalation to 50mg.

 Duration of study 12 weeks.

 Inclusion criteria: Women between the ages of 18 and 89 with complaints of pain related urinary frequency are eligible to participate in the study.

 Exclusion criteria: Patients will be excluded from the study if they have: 1.

 Severe Liver disease, Child-Pugh class c 2.

 Severe Kidney disease, GFR 160/95 (in package insert bp >180/110) 4.

 Urinary retention 5.

 Pregnant, will become pregnant, or are nursing 6.

 History of recurrent urinary tract infection 7.

 Tachycardia: pulse > 100 8.

 Presently on study drug mirabegron; patient must be willing to participate in a 30 day washout period to be eligible for inclusion 9.

 Medications - metoprolol, desipramine, digoxin, propafenone, thioridazine, flecainide, warfarin.

 Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women@highlight

The specific purpose of this study is to provide objective data in prospective open label design (n=40) to support the use of Mirabegron as a treatment for pain related urinary frequency and urgency.

 Women with bladder pain have a poor response to traditional anticholinergic therapy for their symptoms of frequency and urgency.

